SCHEMBL4987320

SCHEMBL4987320

CCOC(=O)CN1C(=O)C(=O)c2ccccc21

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.71
MAPT P10636 4/20 0.68
HTT P42858 1/20 0.68
HSD17B10 Q99714 1/20 0.68
AGTR1 P30556 1/20 0.68
KMT2A Q03164 2/20 0.66
PIN1 Q13526 1/20 0.57
PIN4 Q9Y237 1/20 0.57
TP53 P04637 2/20 0.57
MEN1 O00255 1/20 0.57
GSK3A P49840 1/20 0.55
GSK3B P49841 1/20 0.55
BCHE P06276 2/20 0.54
CES1 P23141 2/20 0.54
TGM2 P21980 1/20 0.54
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18974747 0.86 CES1 (0.59) ALDH1A1MAPTHTTHSD17B10AGTR1
SCHEMBL18955583 0.85 ALDH1A1 (0.66) ALDH1A1MAPTHTTHSD17B10AGTR1
SCHEMBL27703398 0.85 ALDH1A1 (0.72) ALDH1A1MAPTHSD17B10AGTR1KMT2A
SCHEMBL6317939 0.83 ALDH1A1 (0.54) ALDH1A1MAPTHTTHSD17B10AGTR1
SCHEMBL6317943 0.83 ALDH1A1 (0.54) ALDH1A1MAPTHTTHSD17B10AGTR1
SCHEMBL18974294 0.83 ALDH1A1 (0.62) ALDH1A1MAPTHTTHSD17B10AGTR1
SCHEMBL11453331 0.83 ALDH1A1 (0.77) ALDH1A1MAPTHTTHSD17B10KMT2A
SCHEMBL7091522 0.81 ALDH1A1 (0.67) ALDH1A1MAPTHSD17B10AGTR1KMT2A
SCHEMBL18974291 0.81 ALDH1A1 (1.00) ALDH1A1MAPTHSD17B10AGTR1KMT2A
SCHEMBL10430383 0.81 ALDH1A1 (0.64) ALDH1A1MAPTHTTHSD17B10AGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017099695-A1 N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS ISTANBUL UNIVERSITESI REKTORLUGU (TR) 2017-06-15 WO disclosed
CN-103271906-A Use of spiro-oxindole compounds as therapeutic agents XENON PHARMACEUTICALS INC 2013-09-04 CN disclosed
CN-102153562-A Spiro-oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC 2011-08-17 CN disclosed
CN-101631546-A Use of spiro-indolone compounds as therapeutic agents XENON PHARMACEUTICALS INC 2010-01-20 CN disclosed
CN-101213174-A Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2008-07-02 CN disclosed
US-20080125469-A1 Thiadiazole compounds and methods of use thereof WYETH (US) 2008-05-29 US disclosed
CN-101184761-A Spiro-indolone compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2008-05-21 CN disclosed
WO-2007132280-A1 ISATIN AND ITS DERIVATIVES FOR USE AS A MEDICAMENT Szegedi Tudományegyetem (HU) 2007-11-22 WO disclosed
EP-0432648-B1 Isatine derivatives, their preparation and use NEUROSEARCH AS (DK) 1995-08-02 EP disclosed
US-5198461-A Isatine derivatives, their preparation and use NEUROSEARCH A/S (DK) 1993-03-30 US disclosed
US-5192792-A Isatine derivatives, and their method of use WARNER-LAMBERT COMPANY (US) 1993-03-09 US disclosed
US-5164404-A HYDRAZONE DERIVATIVES AND THEIR USE NEUROSEARCH A/S (DK) 1992-11-17 US disclosed
EP-0503349-A1 Hydrazone derivatives, their preparation and use NEUROSEARCH A/S (DK) 1992-09-16 EP disclosed
US-5093364-A 5-FLUOROANTHRANILIC FUNGICIDES SCHERING AGROCHEMICALS LIMITED (GB) 1992-03-03 US disclosed
EP-0432648-A2 Isatine derivatives, their preparation and use NEUROSEARCH A/S (DK) 1991-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125469-A1 Thiadiazole compounds and methods of use thereof ADAMTS5, ADAMTS1, TIMP3 ALDH1A1 388/4885MAPT 1320/4885HTT 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.